Premium
Clinical and molecular aspects of retinoid therapy for acute promyelocytic leukemia
Author(s) -
Warrell Raymond P.
Publication year - 1997
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19970207)70:4<496::aid-ijc25>3.0.co;2-c
Subject(s) - acute promyelocytic leukemia , cancer , citation , medicine , library science , cancer research , oncology , gerontology , retinoic acid , gene , biology , genetics , computer science
As a single agent, all-trans RA produces a higher rate of complete remission in APL than any other drug in any other neoplastic disease. The molecular findings in this illness have been exploited to develop a means of detecting and eradicating minimal residual disease. Compared with other forms of acute myeloid leukemia, this subtype is now associated with the highest proportion of patients in extended disease-free first remission who are presumably cured of their disease. APL is a prototype for understanding the pathogenesis of a malignant disease and the development of novel therapies that are targeted to specific molecular abnormalities.